1887

Abstract

The new lipoglycopeptide dalbavancin has only been approved for acute bacterial skin and skin structure infections. However, its alternative use as a catheter lock solution could facilitate the conservative management of catheter-related bloodstream infection. Our objective was to assess the stability and activity of dalbavancin alone and in combination with heparin against methicillin-resistant (MRSA) and methicillin-resistant (MRSE) biofilms. We also compared the results with those obtained with vancomycin alone and in combination with heparin.

We used a 96-well plate model based on 24 h biofilms of MRSA and MRSE (ATCC 43300, ATCC 35984 and one clinical strain of each). The biofilms were exposed to dalbavancin (0.128 mg ml) and vancomycin (5 mg ml) alone and in combination with heparin (60 IU). The median percentage reductions in metabolic activity, biomass, bacterial load, and cell viability for each solution were compared.

Dalbavancin combined with heparin significantly reduced the median [interquartile range (IQR)] percentage of metabolic activity in MRSA biofilms compared with vancomycin [90.0 % (70.4–92.9 %) versus 35.0 % (14.8–59.6 %), =0.006]. For the remaining variables studied, the combination was not inferior to vancomycin for MRSA and MRSE.

Dalbavancin proved to be active against MRSA and MRSE biofilms. The combination of dalbavancin with heparin is a promising catheter lock solution that has the advantage of locking the catheter at home for 7 days.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000749
2018-07-01
2020-01-19
Loading full text...

Full text loading...

/deliver/fulltext/jmm/67/7/936.html?itemId=/content/journal/jmm/10.1099/jmm.0.000749&mimeType=html&fmt=ahah

References

  1. Dash RP, Babu RJ, Srinivas NR. Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic. Infect Dis 2017;49:483–492 [CrossRef][PubMed]
    [Google Scholar]
  2. Cercenado E. Antimicrobial spectrum of dalbavancin. Mechanism of action and in vitro activity against Gram-positive microorganisms. Enferm Infecc Microbiol Clin 2017;35:9–14 [CrossRef][PubMed]
    [Google Scholar]
  3. Malabarba A, Goldstein BP. Origin, structure, and activity in vitro and in vivo of dalbavancin. J Antimicrob Chemother 2005;55:ii15–ii20 [CrossRef][PubMed]
    [Google Scholar]
  4. Lopez S, Hackbarth C, Romanò G, Trias J, Jabes D et al. In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide. J Antimicrob Chemother 2005;55:ii21–ii24 [CrossRef][PubMed]
    [Google Scholar]
  5. Seltzer E, Dorr MB, Goldstein BP, Perry M, Dowell JA et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis 2003;37:1298–1303 [CrossRef][PubMed]
    [Google Scholar]
  6. Rodríguez-Pardo D. Evaluation of clinical evidence for dalbavancin. Enferm Infecc Microbiol Clin 2017;35:33–37 [CrossRef][PubMed]
    [Google Scholar]
  7. Baldoni D, Furustrand Tafin U, Aeppli S, Angevaare E, Oliva A et al. Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection model. Int J Antimicrob Agents 2013;42:220–225 [CrossRef][PubMed]
    [Google Scholar]
  8. Fernández J, Greenwood-Quaintance KE, Patel R. In vitro activity of dalbavancin against biofilms of staphylococci isolated from prosthetic joint infections. Diagn Microbiol Infect Dis 2016;85:449–451 [CrossRef][PubMed]
    [Google Scholar]
  9. Knafl D, Tobudic S, Cheng SC, Bellamy DR, Thalhammer F et al. Dalbavancin reduces biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE). Eur J Clin Microbiol Infect Dis 2017;36:677–680 [CrossRef][PubMed]
    [Google Scholar]
  10. Raad I, Darouiche R, Vazquez J, Lentnek A, Hachem R et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis 2005;40:374–380 [CrossRef][PubMed]
    [Google Scholar]
  11. Goldstein BP, Jones RN, Fritsche TR, Biedenbach DJ. Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infections. Diagn Microbiol Infect Dis 2006;54:83–87 [CrossRef][PubMed]
    [Google Scholar]
  12. Rappo U GO, Akinapelli K, Mcgregor J et al. Outcomes in patients with Staphylococcus aureus bacteraemia treated with dalbavancin in clinical trials. Poster at European Congress of Clinical Microbiology and Infectious Diseases (P2126). 22–25 april, Vienna 2016
  13. Tatarelli P, Parisini A, del Bono V, Mikulska M, Viscoli C et al. Efficacy of daptomycin lock therapy in the treatment of bloodstream infections related to long-term catheter. Infection 2015;43:107–109 [CrossRef][PubMed]
    [Google Scholar]
  14. Beigi AA, Khansoltani S, Masoudpour H, Atapour AA, Eshaghian A et al. Influence of intralumenal and antibiotic-lock of vancomycin on the rate of catheter removal in the patients with permanent hemodialysis catheters. Saudi J Kidney Dis Transpl 2010;21:54–58[PubMed]
    [Google Scholar]
  15. Krishnasami Z, Carlton D, Bimbo L, Taylor ME, Balkovetz DF et al. Management of hemodialysis catheter-related bacteremia with an adjunctive antibiotic lock solution. Kidney Int 2002;61:1136–1142 [CrossRef][PubMed]
    [Google Scholar]
  16. del Pozo JL, Alonso M, Serrera A, Hernaez S, Aguinaga A et al. Effectiveness of the antibiotic lock therapy for the treatment of port-related enterococci, Gram-negative, or Gram-positive bacilli bloodstream infections. Diagn Microbiol Infect Dis 2009;63:208–212 [CrossRef][PubMed]
    [Google Scholar]
  17. Fortún J, Grill F, Martín-Dávila P, Blázquez J, Tato M et al. Treatment of long-term intravascular catheter-related bacteraemia with antibiotic-lock therapy. J Antimicrob Chemother 2006;58:816–821 [CrossRef][PubMed]
    [Google Scholar]
  18. Park KH, Cho OH, Lee SO, Choi SH, Kim YS et al. Outcome of attempted Hickman catheter salvage in febrile neutropenic cancer patients with Staphylococcus aureus bacteremia. Ann Hematol 2010;89:1163–1169 [CrossRef][PubMed]
    [Google Scholar]
  19. Kim SH, Kang CI, Kim HB, Youn SS, Oh MD et al. Outcomes of Hickman catheter salvage in febrile neutropenic cancer patients with Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 2003;24:897–904 [CrossRef][PubMed]
    [Google Scholar]
  20. Foresti S, di Bella S, Rovelli A, Sala A, Verna M et al. Tigecycline lock therapy for catheter-related bloodstream infection caused by KPC-producing Klebsiella pneumoniae in two pediatric hematological patients. Antimicrob Agents Chemother 2015;59:7919–7920 [CrossRef][PubMed]
    [Google Scholar]
  21. Funalleras G, Fernández-Hidalgo N, Borrego A, Almirante B, Planes AM et al. Effectiveness of antibiotic-lock therapy for long-term catheter-related bacteremia due to Gram-negative bacilli: a prospective observational study. Clin Infect Dis 2011;53:e129-32 [CrossRef][PubMed]
    [Google Scholar]
  22. Peterson WJ, Maya ID, Carlton D, Estrada E, Allon M et al. Treatment of dialysis catheter-related Enterococcus bacteremia with an antibiotic lock: a quality improvement report. Am J Kidney Dis 2009;53:107–111 [CrossRef][PubMed]
    [Google Scholar]
  23. Bookstaver PB, Gerrald KR, Moran RR. Clinical outcomes of antimicrobial lock solutions used in a treatment modality: a retrospective case series analysis. Clin Pharmacol 2010;2:123–130 [CrossRef][PubMed]
    [Google Scholar]
  24. Yen HW, Yang WC, Tarng DC, Yang CY, Chuang CL et al. Daptomycin antibiotic lock therapy for hemodialysis patients with Gram-positive bloodstream infections following use of tunneled, cuffed hemodialysis catheters: retrospective single center analysis. Hemodial Int 2016;20:315–320 [CrossRef][PubMed]
    [Google Scholar]
  25. Sevillano D AL, González N, Buenache N et al. Evaluación comparativa de la actividad de dalbavancina, daptomicina, linezolid y vancomicina en la estrategia de sellado del catéter colonizado por S. aureus resistente a meticilna (SAMR) y de S. epidermidis resistente a meticilina (SEMR). Poster at Congreso de la Sociedad Española de MIcrobiología Clínica y Enfernedades Infecciosas P285. 2017
  26. Meeker DG, Beenken KE, Mills WB, Loughran AJ, Spencer HJ et al. Evaluation of antibiotics active against methicillin-resistant Staphylococcus aureus based on activity in an established biofilm. Antimicrob Agents Chemother 2016;60:5688–5694 [CrossRef][PubMed]
    [Google Scholar]
  27. Alonso B, Lucio J, Pérez-Granda MJ, Cruces R, Sánchez-Carrillo C et al. Does biomass production correlate with metabolic activity in Staphylococcus aureus?. J Microbiol Methods 2016;131:110–112 [CrossRef][PubMed]
    [Google Scholar]
  28. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the infectious diseases society of America. Clin Infect Dis 2009;49:1–45 [CrossRef][PubMed]
    [Google Scholar]
  29. Peeters E, Nelis HJ, Coenye T. Comparison of multiple methods for quantification of microbial biofilms grown in microtiter plates. J Microbiol Methods 2008;72:157–165 [CrossRef][PubMed]
    [Google Scholar]
  30. Pérez LM, Alvarez BL, Codony F, Fittipaldi M, Adrados B et al. A new microtitre plate screening method for evaluating the viability of aerobic respiring bacteria in high surface biofilms. Lett Appl Microbiol 2010;51:331–337 [CrossRef][PubMed]
    [Google Scholar]
  31. Alonso B, Cruces R, Pérez A, Sánchez-Carrillo C, Guembe M et al. Comparison of the XTT and resazurin assays for quantification of the metabolic activity of Staphylococcus aureus biofilm. J Microbiol Methods 2017;139:135–137 [CrossRef][PubMed]
    [Google Scholar]
  32. Billeter M, Zervos MJ, Chen AY, Dalovisio JR, Kurukularatne C et al. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic. Clin Infect Dis 2008;46:577–583 [CrossRef][PubMed]
    [Google Scholar]
  33. Dowell JA, Goldstein BP, Buckwalter M, Stogniew M, Damle B et al. Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic. J Clin Pharmacol 2008;48:1063–1068 [CrossRef][PubMed]
    [Google Scholar]
  34. Burke SL, Rose WE. New pharmacological treatments for methicillin-resistant Staphylococcus aureus infections. Expert Opin Pharmacother 2014;15:483–491 [CrossRef][PubMed]
    [Google Scholar]
  35. Ramírez Hidalgo M, Jover-Sáenz A, García-González M, Barcenilla-Gaite F. Dalbavancin treatment of prosthetic knee infection due to oxacillin-resistant Staphylococcus epidermidis. Enferm Infecc Microbiol Clin 2018;36:142–143 [CrossRef][PubMed]
    [Google Scholar]
  36. Dunne MW, Puttagunta S, Sprenger CR, Rubino C, van Wart S et al. Extended-duration dosing and distribution of dalbavancin into bone and articular tissue. Antimicrob Agents Chemother 2015;59:1849–1855 [CrossRef][PubMed]
    [Google Scholar]
  37. Barnea Y, Lerner A, Aizic A, Navon-Venezia S, Rachi E et al. Efficacy of dalbavancin in the treatment of MRSA rat sternal osteomyelitis with mediastinitis. J Antimicrob Chemother 2016;71:460–463 [CrossRef][PubMed]
    [Google Scholar]
  38. Darouiche RO, Mansouri MD. Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vivo. J Infect 2005;50:206–209 [CrossRef][PubMed]
    [Google Scholar]
  39. Cho JC, Estrada SJ, Beltran AJ, Revuelta MP. Treatment of methicillin-sensitive Staphylococcus aureus bacteremia secondary to septic phlebitis using dalbavancin. J Clin Pharm Ther 2015;40:604–606 [CrossRef][PubMed]
    [Google Scholar]
  40. Lin SH, Liao WH, Lai CC, Liao CH, Tan CK et al. Association between early and late catheter removal and outcome of elderly patients with catheter-related bloodstream infection and persistent bacteremia caused by methicillin-resistant Staphylococcus aureus. J Am Geriatr Soc 2010;58:1197–1199 [CrossRef][PubMed]
    [Google Scholar]
  41. Walsh TJ, Rex JH. All catheter-related candidemia is not the same: assessment of the balance between the risks and benefits of removal of vascular catheters. Clin Infect Dis 2002;34:600–602 [CrossRef][PubMed]
    [Google Scholar]
  42. Rijnders BJ, Peetermans WE, Verwaest C, Wilmer A, van Wijngaerden E et al. Watchful waiting versus immediate catheter removal in ICU patients with suspected catheter-related infection: a randomized trial. Intensive Care Med 2004;30:1073–1080 [CrossRef][PubMed]
    [Google Scholar]
  43. Fernández-Hidalgo N, Gavaldà J, Almirante B, Martín MT, Onrubia PL et al. Evaluation of linezolid, vancomycin, gentamicin and ciprofloxacin in a rabbit model of antibiotic-lock technique for Staphylococcus aureus catheter-related infection. J Antimicrob Chemother 2010;65:525–530 [CrossRef][PubMed]
    [Google Scholar]
  44. Giacometti A, Cirioni O, Ghiselli R, Orlando F, Mocchegiani F et al. Comparative efficacies of quinupristin-dalfopristin, linezolid, vancomycin, and ciprofloxacin in treatment, using the antibiotic-lock technique, of experimental catheter-related infection due to Staphylococcus aureus. Antimicrob Agents Chemother 2005;49:4042–4045 [CrossRef][PubMed]
    [Google Scholar]
  45. Atshan SS, Nor Shamsudin M, Lung LT, Sekawi Z, Pei Pei C et al. Genotypically different clones of Staphylococcus aureus are diverse in the antimicrobial susceptibility patterns and biofilm formations. Biomed Res Int 2013;2013:1–10 [CrossRef][PubMed]
    [Google Scholar]
  46. Hogan S, Zapotoczna M, Stevens NT, Humphreys H, O'Gara JP et al. In vitro approach for identification of the most effective agents for antimicrobial lock therapy in the treatment of intravascular catheter-related infections caused by Staphylococcus aureus. Antimicrob Agents Chemother 2016;60:2923–2931 [CrossRef][PubMed]
    [Google Scholar]
  47. Lebeaux D, Leflon-Guibout V, Ghigo JM, Beloin C. In vitro activity of gentamicin, vancomycin or amikacin combined with EDTA or l-arginine as lock therapy against a wide spectrum of biofilm-forming clinical strains isolated from catheter-related infections. J Antimicrob Chemother 2015;70:1704–1712 [CrossRef][PubMed]
    [Google Scholar]
  48. Siala W, Mingeot-Leclercq MP, Tulkens PM, Hallin M, Denis O et al. Comparison of the antibiotic activities of Daptomycin, Vancomycin, and the investigational Fluoroquinolone Delafloxacin against biofilms from Staphylococcus aureus clinical isolates. Antimicrob Agents Chemother 2014;58:6385–6397 [CrossRef][PubMed]
    [Google Scholar]
  49. Monzón M, Oteiza C, Leiva J, Lamata M, Amorena B et al. Biofilm testing of Staphylococcus epidermidis clinical isolates: low performance of vancomycin in relation to other antibiotics. Diagn Microbiol Infect Dis 2002;44:319–324 [CrossRef][PubMed]
    [Google Scholar]
  50. Bookstaver PB, Rokas KE, Norris LB, Edwards JM, Sherertz RJ et al. Stability and compatibility of antimicrobial lock solutions. Am J Health Syst Pharm 2013;70:2185–2198 [CrossRef][PubMed]
    [Google Scholar]
  51. Anthony TU, Rubin LG. Stability of antibiotics used for antibiotic-lock treatment of infections of implantable venous devices (ports). Antimicrob Agents Chemother 1999;43:2074–2076[PubMed]
    [Google Scholar]
  52. Morales-Molina JA, Mateu-de Antonio J, Grau S, Segura M, Acosta P et al. Stability: a factor to consider in antibiotic-lock solutions. Enferm Infecc Microbiol Clin 2010;28:104–109 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000749
Loading
/content/journal/jmm/10.1099/jmm.0.000749
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error